NICE has recently approved the use of pembrolizumab (Keytruda) for adjuvant treatment of melanoma after resection of the primary site and lymph node removal (after removing lymph nodes that can be felt, or after a sentinel node biopsy). The addition of pembrolizumab (which is an immunotherapy) after melanoma surgery is likely to improve the recurrence-free survival in patients.
THE ROYAL MARSDEN
203 Fulham Road
Chelsea
London
SW3 6JJ
Myles.smithPA@rmh.nhs.uk
020 7808 2785
HCA HOSPITALS
CHELSEA OUTPATIENT CENTRE
280 King’s Road
London
SW3 5AW
MylesSmith.Secretary@hcahealthcare.co.uk
020 3770 5864
Chiswick Outpatients & Diagnostics Centre
347 – 353 Chiswick High Road
Chiswick
London
W4 4HS
MylesSmith.Secretary@hcahealthcare.co.uk
020 3770 5864